

July 9, 2020  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## **Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS**

TOKYO, Japan, July 9, 2020 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that its U.S. licensor for Rigosertib, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova"), announced on July 7, 2020 (EST) that the e-publication of results from a Phase 1 company-sponsored study of oral rigosertib in combination with standard dose azacitidine in the treatment of patients diagnosed with either higher-risk myelodysplastic syndrome (HR-MDS) or acute myeloid leukemia (AML) in the international hematological malignancy journal *Leukemia Research*.

This publication reports the results of an open-label, dose-escalating Phase 1 study with the combination oral of rigosertib and standard dose azacitidine administered sequentially to patients diagnosed with HR-MDS following HMA-failure, or relapsed/refractory AML. The study objectives were to assess safety and determine the recommended Phase 2 dose (RP2D) for future studies. The study evaluated three dose cohorts of oral rigosertib with no dose-limiting toxicities reported. In addition, the oral rigosertib/azacitidine combination demonstrated an overall response rate of 7/9 (78%) in patients with HR-MDS and 2/7 (29%) in patients with AML. The Phase 2 part of the study is ongoing. Additional details are available on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT01926587).

For Onconova's full press release, please visit Onconova's website:  
<https://investor.onconova.com/press-releases>

### **About Rigosertib**

Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activation of RAS as an oncogene-related product, thereby blocking the action of multikinases, including PI3K, and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus killing cancer cells. SymBio obtained the development and commercialization licensing rights for Rigosertib from Onconova in July, 2011 for Japan and Korea.

### **About Onconova Therapeutics, Inc.**

Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel drugs to treat cancer, with an initial focus on myelodysplastic syndromes (MDS). Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. For more information, please visit <https://www.onconova.com>.

### **About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.